Ayurvedic texts known as Samhitas have extolled the many benefits of this widely available green wonder. Yet, due to misconceptions, willful or otherwise had shrouded it for many centuries. While there are numerous medicinal properties that can be applied, misuse of the plant could also have disastrous consequences, especially if used as an addictive derivative. The global medical cannabis market is set to reach $3.2 billion by 2025, according to GlobalData. With big pharma taking notice and interest in the sector, the cannabis industry is at the brink of a revolution. BioSpectrum deep dives in to the fascination of big pharma in the cannabis space, how will this disrupt the cannabis industry and most importantly how the pharmaceutical cannabis sector should be regulated?
In February 2021, Irish firm Jazz pharmaceuticals announced the acquisition of London-based GW Pharma for $7.2 billion. GW is focused on the discovery and development of therapeutics from its proprietary cannabinoid product platform. The company’s lead product Epidiolex was the first plant-derived cannabinoid medicine ever approved by the U.S. Food and Drug Administration (US FDA). This is the first big merger between a pharma company and a cannabis supplier/manufacturer. In recent times, most of the big pharma firms has entered into some sort of agreement with the medical cannabis companies, clearly indicating their growing interest in the sector.
WHY BIG PHARMA IS BETTING ON MEDICAL MARIJUANA?
Bu hikaye BioSpectrum Asia dergisinin April 2021 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin April 2021 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
